Eli Lilly and Company · 12 hours ago
Bioconjugation Scientist
Louisville, CO
Full-time
Onsite
Mid LevelEli Lilly and Company is dedicated to transforming scientific discoveries into groundbreaking medicines. The Bioconjugation Scientist will work in a collaborative team environment to research, design, and develop bioconjugation techniques and technologies, contributing to drug discovery programs.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Research, design, and develop bioconjugation techniques and technologies
Synthesizing compounds
Analyzing bioconjugates
Contributing to the development of drug discovery programs
Conducting experiments
Troubleshooting processes
Optimizing methods
Maintaining detailed documentation
Adhering to laboratory safety and compliance standards
Qualification
Required
Experience with bioconjugation, protein conjugation, and antibody-drug conjugates
Strong foundation in analytical techniques such as HPLC, mass spectrometry, and spectroscopic methods
Knowledge in chemistry, biochemistry, or a related scientific field relevant to bioconjugation
Proficiency in method optimization, troubleshooting, and working with complex biological samples
Excellent communication, problem-solving, and collaboration skills
Ability to manage multiple priorities in a dynamic research environment
Ph.D. or M.S. in Chemistry, Biochemistry, or a related field with relevant experience in bioconjugation
Preferred
Familiarity with regulatory requirements and good laboratory practices (GLP) is a plus
Company
Eli Lilly and Company
We're a medicine company turning science into healing to make life better for people around the world.
Founded in 1876
10001+ employees
H1B Sponsorship
Eli Lilly and Company has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (514)
2024 (236)
2023 (167)
2022 (133)
2021 (57)
2020 (52)
Funding
Current Stage
Public CompanyTotal Funding
$6.5M2024-02-12Post Ipo Debt· $6.5M
1978-01-13IPO
Leadership Team
David Ricks
Chair, CEO
Lucas Montarce
Executive Vice President and Chief Financial Officer
Recent News
2026-01-21
Company data provided by crunchbase